NO20004133L - Antistoffer mot human CD40 - Google Patents

Antistoffer mot human CD40

Info

Publication number
NO20004133L
NO20004133L NO20004133A NO20004133A NO20004133L NO 20004133 L NO20004133 L NO 20004133L NO 20004133 A NO20004133 A NO 20004133A NO 20004133 A NO20004133 A NO 20004133A NO 20004133 L NO20004133 L NO 20004133L
Authority
NO
Norway
Prior art keywords
antibodies
human
Prior art date
Application number
NO20004133A
Other languages
English (en)
Other versions
NO20004133D0 (no
Inventor
Alejandro A Aruffo
Diane Hollenbaugh
Anthony W Siadak
Karen K Berry
Linda J Harris
Barbara A Thorne
Jurgen Bajorath
Herren Wu
William D Huse
Jeffry D Watkins
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20004133D0 publication Critical patent/NO20004133D0/no
Publication of NO20004133L publication Critical patent/NO20004133L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20004133A 1998-02-19 2000-08-18 Antistoffer mot human CD40 NO20004133L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/026,291 US6051228A (en) 1998-02-19 1998-02-19 Antibodies against human CD40
PCT/US1999/002949 WO1999042075A2 (en) 1998-02-19 1999-02-10 Antibodies against human cd40

Publications (2)

Publication Number Publication Date
NO20004133D0 NO20004133D0 (no) 2000-08-18
NO20004133L true NO20004133L (no) 2000-10-18

Family

ID=21830976

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004133A NO20004133L (no) 1998-02-19 2000-08-18 Antistoffer mot human CD40

Country Status (31)

Country Link
US (3) US6051228A (no)
EP (1) EP1054692A4 (no)
JP (1) JP2002503495A (no)
KR (1) KR100564376B1 (no)
CN (1) CN1198647C (no)
AR (1) AR018101A1 (no)
AU (1) AU751064B2 (no)
BG (1) BG65010B1 (no)
BR (1) BR9908045A (no)
CA (1) CA2321165A1 (no)
CO (1) CO4830493A1 (no)
CZ (1) CZ20003008A3 (no)
EE (1) EE200000470A (no)
GE (1) GEP20033016B (no)
HU (1) HUP0100763A3 (no)
ID (1) ID25792A (no)
IL (2) IL137294A0 (no)
LT (1) LT4837B (no)
LV (1) LV12561B (no)
MY (1) MY121464A (no)
NO (1) NO20004133L (no)
NZ (1) NZ505696A (no)
PE (1) PE20000268A1 (no)
PL (1) PL197143B1 (no)
RU (1) RU2220980C2 (no)
SK (1) SK12092000A3 (no)
TR (1) TR200002405T2 (no)
TW (1) TWI226334B (no)
UA (1) UA71909C2 (no)
WO (1) WO1999042075A2 (no)
ZA (1) ZA991307B (no)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
DE69731836T2 (de) * 1996-07-23 2005-12-01 Pangenetics B.V. Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2000066155A1 (en) 1999-04-30 2000-11-09 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
EP1839674A1 (en) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU1590201A (en) * 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
CA2406961A1 (en) * 2000-04-19 2002-02-14 Tanox, Inc. Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US20020197256A1 (en) * 2001-04-02 2002-12-26 Genentech, Inc. Combination therapy
EP2011802A3 (en) * 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
CA2492823A1 (en) * 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP2005510570A (ja) * 2001-11-26 2005-04-21 カイロン コーポレイション 多発性硬化症処置のためのアンタゴニスト抗ｃｄ４０モノクローナル抗体療法
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
CN102174108B (zh) * 2002-03-01 2016-06-29 免疫医疗公司 内在化抗-cd74抗体和使用方法
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
AU2003300842A1 (en) * 2002-12-09 2004-06-30 Tolerrx, Inc. Inducing tolerance in primates
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005044854A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006046935A1 (en) * 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
WO2006108035A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
DK1889065T3 (da) 2005-05-18 2013-09-02 Xoma Technology Ltd Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
ATE485057T1 (de) * 2005-05-26 2010-11-15 Seattle Genetics Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
US7668387B2 (en) * 2005-06-20 2010-02-23 Intel Corporation Selective local transient improvement and peaking for video sharpness enhancement
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
WO2007033369A2 (en) * 2005-09-14 2007-03-22 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets
US20080131914A1 (en) * 2005-09-14 2008-06-05 Ahearn Joseph M Assessing risk of cerebrovascular thrombosis by measuring c4d
US20070202549A1 (en) * 2005-09-14 2007-08-30 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets
WO2007053767A1 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
CN101479375B (zh) * 2006-05-03 2016-03-30 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
MX2009001226A (es) * 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
ES2579323T3 (es) 2007-07-16 2016-08-09 Genentech, Inc. Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
CL2009000062A1 (es) 2008-01-31 2010-05-14 Genentech Inc Anticuerpo humanizado anti cd79b; con modificaciones de cisterna libre; inmunoconjugado que contiene dicho anticuerpo y una droga; polinucleotido que codifica el anticuerpo; vector, celula huesped; composicion farmaceutica y uso de dicha composicion para tratar cancer, preferentemente linfomas.
CN103415534A (zh) 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
BRPI1009458A2 (pt) * 2009-03-10 2016-03-01 Baylor Res Inst vacinas antivirais direcionadas às células de apresentação de antígeno
WO2011085354A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
HUE038788T2 (hu) 2010-03-31 2018-11-28 Boehringer Ingelheim Int Anti-CD40 antitestek
PT2569013T (pt) * 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
AU2012229236B2 (en) 2011-03-11 2017-05-18 Beth Israel Deaconess Medical Center, Inc. Anti-CD40 antibodies and uses thereof
MX354243B (es) 2011-04-21 2018-02-20 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40.
EP3508500A1 (en) * 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40 antibodies and methods of use
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
BR112014009069A2 (pt) 2011-10-13 2020-10-27 Bristol-Myers Squibb Company polipeptídeos de anticorpo que antagonizam cd40l
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CA2936833A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
CA2957146A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
EP3194442A4 (en) * 2014-09-16 2018-05-23 UBI IP Holdings Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
EP3831847A1 (en) 2014-10-29 2021-06-09 Seagen Inc. Dosage and administration of non-fucosylated anti-cd40 antibodies
EP3229586A4 (en) 2014-12-10 2018-10-24 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
BR112017025693A2 (pt) 2015-05-29 2018-08-14 Abbvie Inc. anticorpos anti-cd40 e seus usos
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
CN108368510B (zh) 2015-09-30 2023-09-01 詹森生物科技公司 特异性结合人cd40的激动性抗体和使用方法
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018183041A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR20210033029A (ko) * 2018-07-20 2021-03-25 유큐(베이징) 바이오파마 코., 엘티디 항-cd40 항체 및 그의 용도
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
US20230192840A1 (en) * 2018-12-28 2023-06-22 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody and use thereof
CN111454364B (zh) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 结合cd40的抗体及其用途
JP2022547850A (ja) * 2019-09-03 2022-11-16 バイオ － テラ ソリューションズ、リミテッド 抗ｔｉｇｉｔ免疫阻害剤及び応用
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途
CN117500816A (zh) 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
EP4402174A1 (en) * 2021-09-17 2024-07-24 Novartis AG Methods for prevention of graft rejection in xenotransplantation
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1993011252A1 (en) * 1991-11-26 1993-06-10 The Regents Of The University Of California Cloning vectors for expressing pcr generated variable regions as complete heavy and/or light chain(s)
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1996032495A1 (en) * 1995-04-08 1996-10-17 Lg Chemicals Ltd. Monoclonal antibody specific for human 4-1bb and cell line producing same
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물

Also Published As

Publication number Publication date
GEP20033016B (en) 2003-07-25
AU751064B2 (en) 2002-08-08
CA2321165A1 (en) 1999-08-26
SK12092000A3 (sk) 2002-03-05
CO4830493A1 (es) 1999-08-30
EP1054692A4 (en) 2005-02-23
HUP0100763A2 (hu) 2001-06-28
ID25792A (id) 2000-11-02
CN1198647C (zh) 2005-04-27
HUP0100763A3 (en) 2006-06-28
TWI226334B (en) 2005-01-11
KR20010052174A (ko) 2001-06-25
PL197143B1 (pl) 2008-03-31
WO1999042075A2 (en) 1999-08-26
RU2220980C2 (ru) 2004-01-10
US6413514B1 (en) 2002-07-02
UA71909C2 (en) 2005-01-17
BG104778A (en) 2001-04-30
LV12561B (en) 2001-03-20
US6312693B1 (en) 2001-11-06
BR9908045A (pt) 2000-12-26
IL137294A0 (en) 2001-07-24
KR100564376B1 (ko) 2006-03-27
AR018101A1 (es) 2001-10-31
PL342668A1 (en) 2001-07-02
LT2000080A (en) 2001-04-25
NZ505696A (en) 2003-05-30
TR200002405T2 (tr) 2000-11-21
CZ20003008A3 (cs) 2001-10-17
LV12561A (en) 2000-11-20
JP2002503495A (ja) 2002-02-05
PE20000268A1 (es) 2000-06-15
AU2671699A (en) 1999-09-06
EE200000470A (et) 2001-12-17
CN1307484A (zh) 2001-08-08
WO1999042075A3 (en) 1999-10-14
BG65010B1 (bg) 2006-12-29
IL137294A (en) 2007-08-19
NO20004133D0 (no) 2000-08-18
MY121464A (en) 2006-01-28
ZA991307B (en) 2000-09-20
US6051228A (en) 2000-04-18
EP1054692A2 (en) 2000-11-29
LT4837B (lt) 2001-08-27

Similar Documents

Publication Publication Date Title
NO20004133D0 (no) Antistoffer mot human CD40
HK1061403A1 (en) ANTIBODIES TO HUMAN IL-1ß
DK1049717T3 (da) Antistoffer mod human IL-2
ID28111A (id) Metoda untuk meningkatkan kesehatan kulit
ID22508A (id) Trokar untuk memasukkan implant-implant
ID24314A (id) Tempat umpan bersekat-sekat
NO20042388L (no) Antistoff mot CD40
NO991449D0 (no) Antistoff mot human parathormon-relaterte peptider
DE60024000D1 (de) Lanzette
DE69727923D1 (de) Gehhilfe
ID27841A (id) Turunan-turunan biaril terapeutik
DE60015351D1 (de) Lanzette
NO20041802L (no) Antistoffer mot human vevsfaktor
ID28441A (id) Terapi untuk memperbaiki kesadaran
EE200200150A (et) Preparaat
ID27346A (id) Peralatan pengenal suara
ATE218675T1 (de) Befestigungsmittel
DE69820648D1 (de) Gehhilfe
ID24759A (id) Metoda untuk meningkatkan volume tulang
ID27806A (id) Tungku cemuk
ID23663A (id) Persiapan kaprolaktam
KR19980067229U (ko) 구멍 뚫기 편리한 펀치
ID24748A (id) Metoda untuk membuat silikon oksinitrid
SE9804006D0 (sv) Improvements related to medical containers
ID18671A (id) Metode untuk menghasilkan polisulfida melalui oksidasi elektrolitik

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application